Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 92 Results

Title
Intervention Indication Therapeutic Area Year Actions
Vibostolimab-pembrolizumab for previously untreated PD-L1-positive metastatic non-small cell lung cancer Pembrolizumab-vibostolimab (MK-7684; MK7684A; Vibostolimab) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2023 View  |  Download
Veliparib (ABT-888) with carboplatin and paclitaxel for advanced or metastatic non-squamous (current or former smokers) non-small cell lung cancer Carboplatin (Paraplatin) , Paclitaxel (Taxol; paclitaxel albumin) , Veliparib (ABT-888; NSC 737664) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2017 View  |  Download
Tusamitamab Ravtansine for previously treated advanced Non-Small-Cell Lung Cancer Tusamitamab ravtansine (SAR408701) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2021 View  |  Download
Trastuzumab deruxtecan for treating previously untreated locally advanced or metastatic non-small cell lung cancer with HER2 mutations Trastuzumab deruxtecan (DS-8201a; Enhertu) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2024 View  |  Download
Trastuzumab deruxtecan for HER2 mutant unresectable and/or metastatic non-squamous non-small cell lung cancer – second line Trastuzumab deruxtecan (DS-8201a; Enhertu) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2021 View  |  Download
Tislelizumab with chemotherapy for previously untreated advanced squamous or non-squamous non-small-cell lung cancer Tislelizumab (BGB-A317; BGBA-317) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2021 View  |  Download
Tislelizumab for advanced non-small cell lung cancer after platinum based chemotherapy Tislelizumab (BGB-A317; BGBA-317) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2021 View  |  Download
Tiragolumab with atezolizumab for treating stage III non-small cell lung cancer after platinum-based chemoradiotherapy Atezolizumab (Tecentriq; MPDL3280A) , Tiragolumab (RG-6058; MTIG7192A) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2023 View  |  Download
Tiragolumab with atezolizumab for previously untreated non-small cell lung cancer Atezolizumab (Tecentriq; MPDL3280A) , Tiragolumab (RG-6058; MTIG7192A) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2022 View  |  Download
Tiragolumab with atezolizumab and pemetrexed and carboplatin or cisplatin for previously untreated advanced non-small-cell lung cancer Atezolizumab (Tecentriq; MPDL3280A) , Tiragolumab (RG-6058; MTIG7192A) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2023 View  |  Download
1 2 3 9 10
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications